Jennifer K. Litton, MD

Jennifer K. Litton, MD, discusses challenges determining the optimal sequencing of PARP inhibitors in early-stage triple-negative breast cancer.

Jennifer Keating Litton, MD, discusses research areas of interest in ESR1-mutated, endocrine receptor–positive, HER2-negative breast cancer.

Jennifer Litton, MD, discusses the safety of talazoparib (Talzenna) in the neoadjuvant treatment of patients with germline BRCA1/2-positive, early-stage HER2-negative breast cancer.

Jennifer K. Litton, MD, discusses the phase 3 EMBRACA trial in patients with germline BRCA1/2-mutated metastatic HER2-negative breast cancer. 

Jennifer K. Litton, MD, associate professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the potential advantage of using biosimilars in oncology.